SI1519732T1 - Uporaba vazopeptidaznih inhibitorjev pri zdravljenju nefropatije - Google Patents

Uporaba vazopeptidaznih inhibitorjev pri zdravljenju nefropatije

Info

Publication number
SI1519732T1
SI1519732T1 SI200332139T SI200332139T SI1519732T1 SI 1519732 T1 SI1519732 T1 SI 1519732T1 SI 200332139 T SI200332139 T SI 200332139T SI 200332139 T SI200332139 T SI 200332139T SI 1519732 T1 SI1519732 T1 SI 1519732T1
Authority
SI
Slovenia
Prior art keywords
nephropathy
treatment
vasopeptidase inhibitors
vasopeptidase
inhibitors
Prior art date
Application number
SI200332139T
Other languages
English (en)
Inventor
Stefan Schafer
Wolfgang Linz
Markus Bleich
Jochen Huber
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of SI1519732T1 publication Critical patent/SI1519732T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200332139T 2002-06-28 2003-06-13 Uporaba vazopeptidaznih inhibitorjev pri zdravljenju nefropatije SI1519732T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
PCT/EP2003/006276 WO2004002492A1 (en) 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy
EP20030740247 EP1519732B1 (en) 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy

Publications (1)

Publication Number Publication Date
SI1519732T1 true SI1519732T1 (sl) 2012-05-31

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332139T SI1519732T1 (sl) 2002-06-28 2003-06-13 Uporaba vazopeptidaznih inhibitorjev pri zdravljenju nefropatije

Country Status (39)

Country Link
US (2) US6930103B2 (sl)
EP (1) EP1519732B1 (sl)
JP (1) JP4564354B2 (sl)
KR (1) KR101072235B1 (sl)
CN (1) CN100366254C (sl)
AR (1) AR040343A1 (sl)
AT (1) ATE548040T1 (sl)
AU (1) AU2003280440B2 (sl)
BR (1) BR0312250A (sl)
CA (1) CA2490277C (sl)
CR (1) CR7667A (sl)
CY (1) CY1112905T1 (sl)
DE (1) DE10229180A1 (sl)
DK (1) DK1519732T3 (sl)
EC (1) ECSP045513A (sl)
ES (1) ES2383889T3 (sl)
HK (1) HK1079435A1 (sl)
HN (1) HN2003000193A (sl)
HR (1) HRP20041212B1 (sl)
IL (2) IL165935A0 (sl)
MA (1) MA27281A1 (sl)
MX (1) MXPA04012230A (sl)
NO (1) NO334811B1 (sl)
NZ (1) NZ537480A (sl)
OA (1) OA12871A (sl)
PA (1) PA8576501A1 (sl)
PE (1) PE20040582A1 (sl)
PL (1) PL218070B1 (sl)
PT (1) PT1519732E (sl)
RS (1) RS52478B (sl)
RU (1) RU2336080C2 (sl)
SI (1) SI1519732T1 (sl)
SV (1) SV2004001560A (sl)
TN (1) TNSN04262A1 (sl)
TW (1) TWI326215B (sl)
UA (1) UA82845C2 (sl)
UY (1) UY27869A1 (sl)
WO (1) WO2004002492A1 (sl)
ZA (1) ZA200409382B (sl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
JP2558208B2 (ja) * 1991-03-01 1996-11-27 ゼリア新薬工業株式会社 インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤
ES2106112T3 (es) * 1991-09-27 1997-11-01 Merrell Pharma Inc Derivados de indano-2-mercaptoacetilamida con una actividad inhibidora de encefalinasa y de ace.
ES2117123T3 (es) * 1992-02-14 1998-08-01 Merrell Pharma Inc Derivados de aminocetilmercaptoacetilamida utilizados como inhibidores de la encefalinasa y del enzima de conversion de angiotensina.
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
HUT75160A (en) * 1994-03-24 1997-04-28 Merrell Pharma Inc Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
DE69630465T2 (de) 1995-12-27 2004-07-22 Mitsubishi Pharma Corp. Vorsorge-/heilmittel fur die komplikationen von diabetes
EE05670B1 (et) * 1999-08-30 2013-08-15 Aventis Pharma Deutschland Gmbh Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
MXPA03008613A (es) * 2001-04-12 2003-12-08 Aventis Pharma Gmbh Derivados de mercaptoacetilamida, procedimiento para su preparacion y su uso.
WO2003013434A2 (en) * 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace

Also Published As

Publication number Publication date
AU2003280440B2 (en) 2009-07-16
ES2383889T3 (es) 2012-06-27
MXPA04012230A (es) 2005-02-25
TNSN04262A1 (en) 2007-03-12
PT1519732E (pt) 2012-05-22
WO2004002492A1 (en) 2004-01-08
IL165935A0 (en) 2006-01-15
US20040058911A1 (en) 2004-03-25
ECSP045513A (es) 2005-03-10
OA12871A (en) 2006-09-15
SV2004001560A (es) 2004-02-26
CN1665512A (zh) 2005-09-07
CY1112905T1 (el) 2016-04-13
EP1519732A1 (en) 2005-04-06
NO334811B1 (no) 2014-06-02
US20050171090A1 (en) 2005-08-04
US6930103B2 (en) 2005-08-16
HRP20041212B1 (hr) 2013-06-30
PL372992A1 (en) 2005-08-08
DK1519732T3 (da) 2012-06-18
MA27281A1 (fr) 2005-04-01
UY27869A1 (es) 2003-12-31
RS100704A (en) 2007-02-05
DE10229180A1 (de) 2004-01-29
NZ537480A (en) 2005-11-25
IL165935A (en) 2010-12-30
JP4564354B2 (ja) 2010-10-20
KR20050013642A (ko) 2005-02-04
TWI326215B (en) 2010-06-21
CA2490277C (en) 2011-11-01
TW200406214A (en) 2004-05-01
HN2003000193A (es) 2004-10-27
CN100366254C (zh) 2008-02-06
HRP20041212A2 (en) 2005-06-30
RS52478B (en) 2013-02-28
PL218070B1 (pl) 2014-10-31
ATE548040T1 (de) 2012-03-15
KR101072235B1 (ko) 2011-10-12
CA2490277A1 (en) 2004-01-08
AR040343A1 (es) 2005-03-30
NO20050425L (no) 2005-01-25
PA8576501A1 (es) 2004-02-07
JP2005533815A (ja) 2005-11-10
BR0312250A (pt) 2005-04-26
PE20040582A1 (es) 2004-10-18
UA82845C2 (en) 2008-05-26
US7514423B2 (en) 2009-04-07
CR7667A (es) 2005-06-16
HK1079435A1 (en) 2006-04-07
RU2336080C2 (ru) 2008-10-20
RU2005102087A (ru) 2005-07-10
EP1519732B1 (en) 2012-03-07
AU2003280440A1 (en) 2004-01-19
ZA200409382B (en) 2006-01-25

Similar Documents

Publication Publication Date Title
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL172316A0 (en) Novel compounds and their use in therapy
AU2003293376A8 (en) Anti-angiogenic compounds and their use in cancer treatment
IL172471A0 (en) Gsk-3 inhibitors and uses thereof
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
AU2003213768A8 (en) Use of benzimidazole analogs in the treatment of cell proliferation
AU2003237367A8 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
AU2003281978A8 (en) Compounds for use in treating obesity
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
IL180138A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer
GB0324761D0 (en) Use of compounds in therapy
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
EP1515725A4 (en) USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED ILLNESSES
EP1482916A4 (en) THERAPY BASED ON SCHWANN CELLS AND PHOSPHODIESTERASE INHIBITORS
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003212634A8 (en) Compounds useful in the treatment of cancer
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
GB0207411D0 (en) Azole compounds and their therapeutic use
AU2003206945A8 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
PL380189A3 (pl) Azolidynokarbonitryle i ich zastosowanie jako inhibitory DPP-IV
SG110107A1 (en) Compound and use in treatment
HRP20041212A2 (en) Use of vasopeptidase inhibitors in the treatment of nephropathy
EP1671648A4 (en) PREVENTION AND TREATMENT OF GVHD